OBJECTIVES: This study was designed to test the hypothesis that epinephrine infusion may be a provocative test able to unmask nonpenetrant KCNQ1 mutation carriers. BACKGROUND: The LQT1 form of congenital long QT syndrome is associated with high vulnerability to sympathetic stimulation and appears with incomplete penetrance. METHODS: The 12-lead electrocardiographic parameters before and after epinephrine infusion were compared among 19 mutation carriers with a baseline corrected QT interval (QTc) of > or =460 ms (Group I), 15 mutation carriers with a QTc of <460 ms (Group II), 12 nonmutation carriers (Group III), and 15 controls (Group IV). RESULTS: The mean corrected Q-Tend (QTce), Q-Tpeak (QTcp), and Tpeak-end (Tcp-e) intervals among 12-leads before epinephrine were significantly larger in Group I than in the other three groups. Epinephrine (0.1 microg/kg/min) increased significantly the mean QTce, QTcp, Tcp-e, and the dispersion of QTcp in Groups I and II, but not in Groups III and IV. The sensitivity and specificity of QTce measurements to identify mutation carriers were 59% (20/34) and 100% (27/27), respectively, before epinephrine, and the sensitivity was substantially improved to 91% (31/34) without the expense of specificity (100%, 27/27) after epinephrine. The mean QTce, QTcp, and Tcp-e before and after epinephrine were significantly larger in 15 symptomatic than in 19 asymptomatic mutation carriers in Groups I and II, and the prolongation of the mean QTce with epinephrine was significantly larger in symptomatic patients. CONCLUSIONS: Epinephrine challenge is a powerful test to establish electrocardiographic diagnosis in silent LQT1 mutation carriers, thus allowing implementation of prophylactic measures aimed at reducing sudden cardiac death.
OBJECTIVES: This study was designed to test the hypothesis that epinephrine infusion may be a provocative test able to unmask nonpenetrant KCNQ1 mutation carriers. BACKGROUND: The LQT1 form of congenital long QT syndrome is associated with high vulnerability to sympathetic stimulation and appears with incomplete penetrance. METHODS: The 12-lead electrocardiographic parameters before and after epinephrine infusion were compared among 19 mutation carriers with a baseline corrected QT interval (QTc) of > or =460 ms (Group I), 15 mutation carriers with a QTc of <460 ms (Group II), 12 nonmutation carriers (Group III), and 15 controls (Group IV). RESULTS: The mean corrected Q-Tend (QTce), Q-Tpeak (QTcp), and Tpeak-end (Tcp-e) intervals among 12-leads before epinephrine were significantly larger in Group I than in the other three groups. Epinephrine (0.1 microg/kg/min) increased significantly the mean QTce, QTcp, Tcp-e, and the dispersion of QTcp in Groups I and II, but not in Groups III and IV. The sensitivity and specificity of QTce measurements to identify mutation carriers were 59% (20/34) and 100% (27/27), respectively, before epinephrine, and the sensitivity was substantially improved to 91% (31/34) without the expense of specificity (100%, 27/27) after epinephrine. The mean QTce, QTcp, and Tcp-e before and after epinephrine were significantly larger in 15 symptomatic than in 19 asymptomatic mutation carriers in Groups I and II, and the prolongation of the mean QTce with epinephrine was significantly larger in symptomatic patients. CONCLUSIONS:Epinephrine challenge is a powerful test to establish electrocardiographic diagnosis in silent LQT1 mutation carriers, thus allowing implementation of prophylactic measures aimed at reducing sudden cardiac death.
Authors: Lee W Gemma; Gregory M Ward; Mary M Dettmer; Jennifer L Ball; Peter J Leo; Danielle N Doria; Elizabeth S Kaufman Journal: J Cardiovasc Electrophysiol Date: 2011-06-02
Authors: Arnon Adler; Christian van der Werf; Pieter G Postema; Raphael Rosso; Zahir A Bhuiyan; Jonathan M Kalman; Jitendra K Vohra; Milton E Guevara-Valdivia; Manlio F Marquez; Amir Halkin; Jesaia Benhorin; Charles Antzelevitch; Arthur A M Wilde; Sami Viskin Journal: Heart Rhythm Date: 2012-01-31 Impact factor: 6.343
Authors: Anna-Mari Hekkala; Heikki Swan; Matti Viitasalo; Heikki Väänänen; Lauri Toivonen Journal: Ann Noninvasive Electrocardiol Date: 2011-04 Impact factor: 1.468
Authors: Ricardo Caballero; Raquel G Utrilla; Irene Amorós; Marcos Matamoros; Marta Pérez-Hernández; David Tinaquero; Silvia Alfayate; Paloma Nieto-Marín; Guadalupe Guerrero-Serna; Qing-Hua Liu; Roberto Ramos-Mondragón; Daniela Ponce-Balbuena; Todd Herron; Katherine F Campbell; David Filgueiras-Rama; Rafael Peinado; José L López-Sendón; José Jalife; Eva Delpón; Juan Tamargo Journal: Proc Natl Acad Sci U S A Date: 2017-01-03 Impact factor: 11.205
Authors: Sami Viskin; Raphael Rosso; Ori Rogowski; Bernard Belhassen; Aviva Levitas; Abraham Wagshal; Amos Katz; Dana Fourey; David Zeltser; Antonio Oliva; Guido D Pollevick; Charles Antzelevitch; Uri Rozovski Journal: Eur Heart J Date: 2005-08-16 Impact factor: 29.983